Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Piedad Reche-Molina"'
Autor:
Alfonso Yubero-Esteban, Piedad Reche-Molina, Carmen Salvador Coloma, Purificación Estévez-García, Luis Manso, Marcos Iglesias Campos, Arantzazu Barquin, Raul Marquez, Ana Santaballa, Julia Calzas, Ana Herrero, Victoria Casado, Julia Madani, Maria Merino, Gloria Marquina, Jesus Alarcon Company, Lydia Gaba, Jose Fuentes Pradera, Antonio Gonzalez Martin, Maria Luisa Sanchez Lorenzo
Publikováno v:
Journal of Clinical Oncology. 40:e17598-e17598
e17598 Background: Rucaparib is a PARP inhibitor (PARPi) approved as maintenance therapy for platinum (Pt)-sensitive recurrent high-grade ovarian cancer (HGOC), and as treatment for BRCA-mutant HGOC patients. To date, there is little evidence about t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35357b7514f82b11ae213ede72dccbfa
https://doi.org/10.1200/jco.2022.40.16_suppl.e17598
https://doi.org/10.1200/jco.2022.40.16_suppl.e17598
Autor:
Alfonso Yubero-Esteban, Arantzazu Barquin, Lydia Gaba, Marcos Iglesias Campos, Piedad Reche-Molina, Carmen Salvador Coloma, Jesus Alarcon Company, Luis Manso, Raul Marquez, Jose Fuentes Pradera, Julia Madani, Manuel Constenla Figueiras, Maria Gutierrez-Toribio, Purificación Estévez-García, Ana Santaballa, Maria Luisa Sanchez Lorenzo, Julia Calzas, Ana Herrero, Alvaro Taus, Antonio Gonzalez Martin
Publikováno v:
Journal of Clinical Oncology. 40:e17562-e17562
e17562 Background: Rucaparib is a PARP inhibitor approved for the treatment of high-grade ovarian cancer (HGOC). Clinical trials have demonstrated its benefit both as maintenance therapy (MTN) for platinum (Pt)-sensitive recurrent HGOC, and as treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4c1d2e535fcfd2ecf856d876c38e5087
https://doi.org/10.1200/jco.2022.40.16_suppl.e17562
https://doi.org/10.1200/jco.2022.40.16_suppl.e17562